Icon Plc (NASDAQ:ICLR) is a contract research organization (“CRO”). In the Q3 2024 letter, I highlighted our investment in Medpace another CRO that directly competes with Icon.

It has been about a month since the last earnings report for Icon PLC (ICLR). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain ...

More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain ...

Icon PLC expects full-year earnings in the range of $12.75 to $14.25 per share, with revenue in the range of $7.75 billion to $8.15 billion. _____ This story was generated by Automated Insights ...

Right now, year-over-year cash flow growth for Icon PLC is 8.2%, which is higher than many of its peers. In fact, the rate compares to the industry average of -13.8%.

Contract research firm ICON Plc said on Wednesday it is partnering with the U.S. government for a clinical trial to test the effectiveness of next generation COVID-19 vaccine candidates. May 10, 2023 ...